EA038176B9 - Pyrrolo[1,2,5]benzothiadiazepine derivatives and use thereof in treating a disease caused by hepatitis b virus - Google Patents

Pyrrolo[1,2,5]benzothiadiazepine derivatives and use thereof in treating a disease caused by hepatitis b virus

Info

Publication number
EA038176B9
EA038176B9 EA201991910A EA201991910A EA038176B9 EA 038176 B9 EA038176 B9 EA 038176B9 EA 201991910 A EA201991910 A EA 201991910A EA 201991910 A EA201991910 A EA 201991910A EA 038176 B9 EA038176 B9 EA 038176B9
Authority
EA
Eurasian Patent Office
Prior art keywords
treating
pyrrolo
hepatitis
virus
disease caused
Prior art date
Application number
EA201991910A
Other languages
Russian (ru)
Other versions
EA201991910A1 (en
EA038176B1 (en
Inventor
Хайин Хэ
Цзин ВАН
Чжигань ЦЗЯН
Ясюнь Ян
Пэн Шао
Чэнь ЧЖАН
Цзянь Ли
Шухуэй Чэнь
Original Assignee
Фуцзянь Косантер Фармасьютикал Ко., Лтд.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Фуцзянь Косантер Фармасьютикал Ко., Лтд. filed Critical Фуцзянь Косантер Фармасьютикал Ко., Лтд.
Priority claimed from PCT/CN2018/075995 external-priority patent/WO2018153285A1/en
Publication of EA201991910A1 publication Critical patent/EA201991910A1/en
Publication of EA038176B1 publication Critical patent/EA038176B1/en
Publication of EA038176B9 publication Critical patent/EA038176B9/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
    • C07D513/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains two hetero rings
    • C07D513/04—Ortho-condensed systems

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)

Abstract

Disclosed in the invention are a compound represented by formula (I), a tautomer thereof or a pharmaceutically acceptable salt, and applications thereof in the preparation of drugs for treating HBV-related diseases.
EA201991910A 2018-01-04 2018-02-09 Pyrrolo[1,2,5]benzothiadiazepine derivatives and use thereof in treating a disease caused by hepatitis b virus EA038176B9 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
CN201810008592 2018-01-04
PCT/CN2018/075995 WO2018153285A1 (en) 2017-02-23 2018-02-09 Tri-cycle compound and applications thereof

Publications (3)

Publication Number Publication Date
EA201991910A1 EA201991910A1 (en) 2020-01-23
EA038176B1 EA038176B1 (en) 2021-07-19
EA038176B9 true EA038176B9 (en) 2021-09-07

Family

ID=69374475

Family Applications (1)

Application Number Title Priority Date Filing Date
EA201991910A EA038176B9 (en) 2018-01-04 2018-02-09 Pyrrolo[1,2,5]benzothiadiazepine derivatives and use thereof in treating a disease caused by hepatitis b virus

Country Status (1)

Country Link
EA (1) EA038176B9 (en)

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN102060786A (en) * 2011-01-20 2011-05-18 天津大学 4-(substituted-1,3-diyne)-4-(trifluoromethyl)-3,4-dihydro substituted quinazoline-2-ketone compound as well as preparation method and application thereof
CN105102451A (en) * 2013-04-03 2015-11-25 爱尔兰詹森科学公司 N-phenyl-carboxamide derivatives and the use thereof as medicaments for the treatment of hepatitis b
CN106255684A (en) * 2013-11-14 2016-12-21 诺维拉治疗公司 Azepan derivatives and the method for the treatment of hepatitis B infection
CN106459032A (en) * 2014-05-13 2017-02-22 豪夫迈·罗氏有限公司 Novel dihydroquinolizinones for the treatment and prophylaxis of hepatitis b virus infection

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN102060786A (en) * 2011-01-20 2011-05-18 天津大学 4-(substituted-1,3-diyne)-4-(trifluoromethyl)-3,4-dihydro substituted quinazoline-2-ketone compound as well as preparation method and application thereof
CN105102451A (en) * 2013-04-03 2015-11-25 爱尔兰詹森科学公司 N-phenyl-carboxamide derivatives and the use thereof as medicaments for the treatment of hepatitis b
CN106255684A (en) * 2013-11-14 2016-12-21 诺维拉治疗公司 Azepan derivatives and the method for the treatment of hepatitis B infection
CN106459032A (en) * 2014-05-13 2017-02-22 豪夫迈·罗氏有限公司 Novel dihydroquinolizinones for the treatment and prophylaxis of hepatitis b virus infection

Also Published As

Publication number Publication date
EA201991910A1 (en) 2020-01-23
EA038176B1 (en) 2021-07-19

Similar Documents

Publication Publication Date Title
SA520420033B1 (en) Pharmaceutical compounds
ZA202006378B (en) N-heterocyclic five-membered ring-containing capsid protein assembly inhibitor, pharmaceutical composition thereof, and use thereof
PH12019501688A1 (en) Pyridine derivative as ask1 inhibitor and preparation method and use thereof
SG11201901894TA (en) Anti-influenza virus pyrimidine derivatives
PH12018550201A1 (en) Hepatitis b antiviral agents
WO2019143902A3 (en) Substituted heterocycles as antiviral agents
PH12018550120A1 (en) Steroid derivative fxr agonist
PH12021551116A1 (en) Functionalized heterocycles as antiviral agents
PH12019501955A1 (en) Tri-cycle compound and applications thereof
MX2017007814A (en) Polycyclic-carbamoylpyridone compounds and their pharmaceutical use.
MX2018009944A (en) Process for the preparation of 4-phenyl-5-alkoxycarbonyl-2-thiazo l-2-yl-1,4-dihydropyrimidin-6-yl]methyl]-3-oxo-5,6,8,8a-tetrahyd ro-1h-imidazo[1,5-a]pyrazin-2-yl]-carboxylic acid.
MX2019013815A (en) Hepatitis b virus surface antigen inhibitor.
MX2021003253A (en) Functionalized heterocycles as antiviral agents.
MX2021014575A (en) Fused heterocyclic derivatives.
MX2021007247A (en) Rapamycin derivatives.
MX2021012105A (en) Pyrrole compounds.
MX2022006333A (en) Tri-heterocyclic compound as jak inhibitor, and use thereof.
PH12018502735A1 (en) Liver delivery-based antiviral precursor drug nucleoside cyclophosphate compound and use thereof
GB2590189A9 (en) Lycorine derivatives, pharmaceutical composite thereof and usage therefor
JOP20200327A1 (en) Cyanotriazole compounds and uses thereof
MX2022005951A (en) Pyrrolotriazine compounds acting as mnk inhibitor.
MX2021014458A (en) Tricyclic compounds.
EA038176B9 (en) Pyrrolo[1,2,5]benzothiadiazepine derivatives and use thereof in treating a disease caused by hepatitis b virus
AU2019296118A8 (en) Isothiazolo(5,4-d)pyrimidine compound as IRAK4 inhibitor
MX2021014576A (en) Fused heterocyclic derivatives as antiviral agents.

Legal Events

Date Code Title Description
TH4A Publication of the corrected specification to eurasian patent